However, the company said it has not received any communication from the market regulator with respect to reopening of insider trading issue.
On the NSE, the scrip fell 2.72 per cent to close at Rs 443.
Sun Pharma had slumped 7.5 per cent on the bourses Monday.
Sebi is likely to reopen an insider trading case against Sun Pharmaceutical Industries as well as probe alleged lapses by some of its promoters and other entities in raising funds overseas, PTI reported on Friday citing sources.
In an investors call on Monday, Shanghvi, Sun Pharma founder and MD, said that as of now the company has not received any query from Sebi with regard to whistle-blower complaint and not received any information from Sebi with respect to reopening insider trading issue.
"We are following the highest levels of corporate governance at Sun Pharma," Shanghvi had said.
In August 2017, Sun Pharmaceutical, its managing director Shanghvi and nine other entities settled an insider trading probe on payment of Rs 18 lakh towards settlement charges.
(With inputs from agencies.)